World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
23822
World Ranking
15672
National Ranking
1445

Mark Bower publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mark Bower sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 523 publications — 62nd percentile

62% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mark Bower D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mark Bower sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mark Bower is affiliated with Imperial College London in the United Kingdom. Their research primarily focuses on Medicine, with a significant concentration in Oncology, Infectious Diseases, Pathology and Forensic Medicine, Neurology, and Genetics. The subfields indicate a broad and interdisciplinary approach to medical research.

The main topics of their work include:

  • Viral-associated cancers and disorders
  • COVID-19 and healthcare impacts
  • Lymphoma Diagnosis and Treatment
  • COVID-19 Clinical Research Studies
  • Chronic Lymphocytic Leukemia Research
  • Cancer Immunotherapy and Biomarkers
  • CNS Lymphoma Diagnosis and Treatment

Mark Bower has contributed to several recent papers that address various aspects of oncology and infectious diseases, particularly focusing on COVID-19's impact on cancer patients. Notable publications include:

  • "Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer" (2020) published in Cancer Discovery
  • "Castleman disease" (2021) published in Nature Reviews Disease Primers
  • "2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0" (2020) published in HIV Medicine
  • "Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study" (2021) published in The Lancet Oncology
  • "Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study" (2022) published in The Lancet Oncology

Frequent co-authors collaborating with Mark Bower include:

  • David J. Pinato
  • Juan Aguilar-Company
  • Alessandra Gennari
  • Ramón Salazar
  • Joan Brunet

Mark Bower's publications often appear in established journals such as:

  • Journal of Clinical Oncology
  • Blood
  • Annals of Oncology
  • The Lancet Oncology
  • Blood Advances

Best Publications

  • A trithorax-like gene is interrupted by chromosome 11q23 translocations in acute leukaemias.

    Malek Djabali;Licia Selleri;Pauline Parry;Mark Bower

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012

    Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito

  • Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.

    David J. Pinato;David J. Pinato;Sarah Howlett;Diego Ottaviani;Heather Urus

  • Antibacterial Prophylaxis after Chemotherapy for Solid Tumors and Lymphomas

    Michael Cullen;Neil Steven;Lucinda Billingham;Claire Gaunt

  • Highly Active Antiretroviral Therapy and the Incidence of Non–AIDS-Defining Cancers in People With HIV Infection

    Thomas Powles;David Robinson;Justin Stebbing;Jonathan Shamash

  • EMA/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients.

    M. Bower;E.S. Newlands;L. Holden;D. Short

  • Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: Prognostic factors and role of postsurgery chemotherapy - Results from an international study group

    Karim Fizazi;Sergei Tjulandin;Roberto Salvioni;José R. Germà-Lluch

  • Phase I Trial of Temozolomide Using an Extended Continuous Oral Schedule

    Cathryn S. Brock;Edward S. Newlands;Steven R. Wedge;Mark Bower

  • Immune Reconstitution Inflammatory Syndrome Associated With Kaposi's Sarcoma

    M. Bower;M. Nelson;A.M. Young;C. Thirlwell

  • Fifty years of multicentric Castleman's disease

    Ashita Waterston;Mark Bower

  • A meta-analysis of transient elastography for the detection of hepatic fibrosis.

    Justin Stebbing;Lavanta Farouk;George Panos;Mike Anderson

  • British HIV Association guidelines for HIV-associated malignancies 2014

    M Bower;S Collins;C Cottrill;K Cwynarski

  • British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.).

    Ian Williams;Ian Williams;Duncan Churchill;Jane Anderson;Marta Boffito

  • Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.

    M. Bower;E. S. Newlands;N. M. Bleehen;M. Brada

  • Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy.

    Gail V. Matthews;Mark Bower;Sundhiya Mandalia;Tom Powles

  • HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome?

    Mark Bower;Tom Powles;Tom Newsom-Davis;Christina Thirlwell

  • Brief Communication: Rituximab in HIV-associated Multicentric Castleman Disease

    Mark Bower;Tom Powles;Sarah Williams;Tom Newsom Davis

  • An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.

    M Nelson;S Portsmouth;J Stebbing;M Atkins

  • AIDS-related malignancies: changing epidemiology and the impact of highly active antiretroviral therapy.

    Mark Bower;Carlo Palmieri;Tony Dhillon

  • The Charing Cross Hospital experience with temozolomide in patients with gliomas.

    E.S. Newlands;S.M. O'Reilly;M.G. Glaser;M. Bower

Frequent Co-Authors

Justin Stebbing
Justin Stebbing Imperial College London
Mark Nelson
Mark Nelson Imperial College London
Brian Gazzard
Brian Gazzard St Bartholomew's Hospital
Mark Nelson
Mark Nelson University of Vermont
Thomas Powles
Thomas Powles Queen Mary University of London
Chloe Orkin
Chloe Orkin Queen Mary University of London
Frances Gotch
Frances Gotch Imperial College London
Gordon J. S. Rustin
Gordon J. S. Rustin Mount Vernon Hospital
Alan Winston
Alan Winston Imperial College London
Caroline Sabin
Caroline Sabin University College London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in expanding your healthcare career options beyond traditional MD and DO programs, several flexible online degree pathways exist. For those with a non-nursing background who wish to move into advanced practice quickly, direct entry msn programs for non-nursing majors online offer accelerated entry into the nursing field. These programs allow you to earn a master’s in nursing—often in less time and with greater flexibility.

Alternatively, many students begin their healthcare careers with practical programs such as adn nursing programs. These Associate Degree in Nursing pathways can be more accessible and shorter than traditional bachelor’s degrees, helping you enter the workforce faster.

If you’re interested in the administrative side of healthcare, consider medical billing and coding schools with financial aid. These programs can often be completed online and offer support for those who qualify.

For those seeking alternative nursing options, some schools now provide absn programs that don't require teas exams, helping applicants bypass common standardized testing barriers.

Best Scientists Citing Mark Bower

Trending Scientists

Recently Published Articles